Abstract
Bone marrow malignancies including multiple myeloma are treated by the myeloablative radiotherapy and subsequent stem cell transplantation. Radiopharmaceuticals are used for the selective delivery of radiation absorbed dose to bone marrow. In this work, the radiation absorbed dose of various organs of the adult man from 166Ho-EDTMP radiopharmaceutical was estimated based on biodistribution data in Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology for extrapolation of %IA of organs from animal to human were applied. The results shows that, more than 61% of injected activity is cumulated on the surface of the trabecular and cortical bones. Red marrow and osteogenic cells radiation absorbed doses were estimated to about 1.4 and 3.1 mGy/MBq, respectively. Compared to other aminophosphonate radiopharmaceuticals, 166Ho-EDTMP requires a minimum activity to deliver a therapeutic dose of 25 Gy to the red bone marrow. The result were compared with available data from literature.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
